Senexin A

CDK8 inhibitor CAS# 1366002-50-7

Senexin A

Catalog No. BCC7980----Order now to get a substantial discount!

Product Name & Size Price Stock
Senexin A: 5mg $127 In Stock
Senexin A: 10mg Please Inquire In Stock
Senexin A: 20mg Please Inquire Please Inquire
Senexin A: 50mg Please Inquire Please Inquire
Senexin A: 100mg Please Inquire Please Inquire
Senexin A: 200mg Please Inquire Please Inquire
Senexin A: 500mg Please Inquire Please Inquire
Senexin A: 1000mg Please Inquire Please Inquire
Related Products

Quality Control of Senexin A

Number of papers citing our products

Chemical structure

Senexin A

3D structure

Chemical Properties of Senexin A

Cas No. 1366002-50-7 SDF Download SDF
PubChem ID 56927063 Appearance Powder
Formula C17H14N4 M.Wt 274.3
Type of Compound N/A Storage Desiccate at -20°C
Solubility DMSO : ≥ 100 mg/mL (364.54 mM)
*"≥" means soluble, but saturation unknown.
Chemical Name 4-(2-phenylethylamino)quinazoline-6-carbonitrile
SMILES C1=CC=C(C=C1)CCNC2=NC=NC3=C2C=C(C=C3)C#N
Standard InChIKey XBJCNHGQFJFCOY-UHFFFAOYSA-N
Standard InChI InChI=1S/C17H14N4/c18-11-14-6-7-16-15(10-14)17(21-12-20-16)19-9-8-13-4-2-1-3-5-13/h1-7,10,12H,8-9H2,(H,19,20,21)
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Biological Activity of Senexin A

DescriptionSenexin A is a CDK8 inhibitor with an IC50 of 280 nM.In Vitro:Senexin A inhibits CDK8 and CDK19 ATP site binding with Kd50 of 0.83 μM and 0.31 μM, respectively and CDK8 kinase activity with IC50 of 0.28 μM. Senexin A inhibits β-catenin–dependent transcription in HCT116 colon carcinoma cells. The induction of transcription factor EGR1 upon serum starvation, followed by readdition of serum, is strongly inhibited by Senexin A in HT1080 cells. Senexin A inhibits only p21-induced transcription but not other biological effects of p21. Senexin A also decreases the expression of many secreted tumor-promoting factors in doxorubicin-treated wild-type HCT116 cells[1].In Vivo:Five daily treatment of Senexin A fully reverses tumor-promoting effect of chemotherapy. Senexin A shows no detectable toxicity and no significant effects on body weight, organ weights, or blood cell counts in C57BL/6 mice during the treatment. This effect of doxorubicin treatment is completely abolished, however, when doxorubicin injection is followed by administration of Senexin A. Senexin A treatment strongly improves the response of A549/MEF tumors to doxorubicin[1].

References:
[1]. Porter DC, et al. Cyclin-dependent kinase 8 mediates chemotherapy-induced tumor-promoting paracrine activities. Proc Natl Acad Sci U S A. 2012 Aug 21;109(34):13799-804.

Protocol

Animal Administration [1]
Mice: Senexin A toxicity study is conducted by Taconic in C57BL/6 mice, using five mice per group treated with 20 mg/kg Senexin A or carrier (80% propylene glycol), with five daily i.p. injections. Mice are weighed on days 3 and 6, and killed on day 6. Organ weights are determined for brain, kidney, thymus, spleen, lung, and liver. Terminal blood samples are analyzed to determine the numbers of total white blood cells, neutrophils, lymphocytes, monocytes, eosinophils, and basophils[1].

References:
[1]. Porter DC, et al. Cyclin-dependent kinase 8 mediates chemotherapy-induced tumor-promoting paracrine activities. Proc Natl Acad Sci U S A. 2012 Aug 21;109(34):13799-804.

Senexin A Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

Senexin A Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of Senexin A

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 3.6456 mL 18.2282 mL 36.4564 mL 72.9129 mL 91.1411 mL
5 mM 0.7291 mL 3.6456 mL 7.2913 mL 14.5826 mL 18.2282 mL
10 mM 0.3646 mL 1.8228 mL 3.6456 mL 7.2913 mL 9.1141 mL
50 mM 0.0729 mL 0.3646 mL 0.7291 mL 1.4583 mL 1.8228 mL
100 mM 0.0365 mL 0.1823 mL 0.3646 mL 0.7291 mL 0.9114 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University

Background on Senexin A

IC50: 280 nM

Senexin A is a Cyclin-dependent kinase 8 (CDK8) inhibitor.

CDK8 is an oncogenic CDK family member that plays no role in cell-cycle progression but regulates several transcriptional programs involved in carcinogenesis and the stem-cell phenotype. CDK8 also cooperates in the formation of internucleolar bodies, where CDK8 accumulates.

In vitro: Senexin A inhibited p21-caused induction of CMV-GFP when GFP expression was normalized either by relative cell number or by the protein amount. p21 was shown to activate NF-κB–dependent transcription, and Senexin A could inhibit p21-stimulated activity of the consensus NF-κB–dependent promoter. Senexin A had no effect on p21 induction by IPTG, on p21-induced senescent phenotype, or on cell growth with or without p21 [1].

In vivo: Previous study tested Senexin A combined with MEF for the in vivo chemosensitization of xenografts formed by tumor cells. SCID mice were injected with A549 cells mixed with MEF. Once tumors stably formed, mice were treated by a single injection of doxorubicin, with five daily injections of either vehicle or Senexin A. Results showed that Senexin A treatment strongly improved the response of A549/MEF tumors to doxorubicin [1].

Clinical trial: N/A

Reference:
[1] Donald C.  Porter,Elena Farmaki,Serena Altilia et al. Cyclin-dependent kinase 8 mediates chemotherapy-induced tumor-promoting paracrine activities. Proc Natl Acad Sci U S A. 2012 Aug 21; 109(34): 13799–13804.

Featured Products
New Products
 

References on Senexin A

CDK8 Kinase Activity Promotes Glycolysis.[Pubmed:29117556]

Cell Rep. 2017 Nov 7;21(6):1495-1506.

Aerobic glycolysis, also known as the Warburg effect, is a hallmark of cancerous tissues. Despite its importance in cancer development, our understanding of mechanisms driving this form of metabolic reprogramming is incomplete. We report here an analysis of colorectal cancer cells engineered to carry a single point mutation in the active site of the Mediator-associated kinase CDK8, creating hypomorphic alleles sensitive to bulky ATP analogs. Transcriptome analysis revealed that CDK8 kinase activity is required for the expression of many components of the glycolytic cascade. CDK8 inhibition impairs glucose transporter expression, glucose uptake, glycolytic capacity and reserve, as well as cell proliferation and anchorage-independent growth, both in normoxia and hypoxia. Importantly, CDK8 impairment sensitizes cells to pharmacological glycolysis inhibition, a result reproduced with Senexin A, a dual inhibitor of CDK8/CDK19. Altogether, these results contribute to our understanding of CDK8 as an oncogene, and they justify investigations to target CDK8 in highly glycolytic tumors.

Description

Senexin A is a CDK8 inhibitor with an IC50 of 280 nM.

Keywords:

Senexin A,1366002-50-7,Natural Products,Cyclin-Dependent Kinases, buy Senexin A , Senexin A supplier , purchase Senexin A , Senexin A cost , Senexin A manufacturer , order Senexin A , high purity Senexin A

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: